Nebicapone

DRUG3 trials

Sponsors

Bial - Portela C S.A.

Conditions

Parkinson DiseaseParkinson's Disease

Phase 1

Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202

CompletedNCT02772627

Bial - Portela C S.A.Parkinson's Disease

Start: 2001-09-30End: 2001-12-31Updated: 2016-05-13

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg

CompletedNCT03097211

Bial - Portela C S.A.Parkinson Disease

Start: 2006-07-17End: 2006-10-20Updated: 2017-03-31

Phase 2

Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With Wearingoff Phenomenon

CompletedNCT03103399

Bial - Portela C S.A.Parkinson Disease

Start: 2006-09-26End: 2007-09-21Updated: 2017-04-06